638 related articles for article (PubMed ID: 29254276)
1. Review: Oncolytic virotherapy, updates and future directions.
Fountzilas C; Patel S; Mahalingam D
Oncotarget; 2017 Nov; 8(60):102617-102639. PubMed ID: 29254276
[TBL] [Abstract][Full Text] [Related]
2. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract][Full Text] [Related]
3. Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy.
Zhang T; Jou TH; Hsin J; Wang Z; Huang K; Ye J; Yin H; Xing Y
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769745
[TBL] [Abstract][Full Text] [Related]
4. The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
6. Immune System, Friend or Foe of Oncolytic Virotherapy?
Filley AC; Dey M
Front Oncol; 2017; 7():106. PubMed ID: 28589085
[TBL] [Abstract][Full Text] [Related]
7. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
8. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
Feola S; Russo S; Ylösmäki E; Cerullo V
Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers.
Scanlan H; Coffman Z; Bettencourt J; Shipley T; Bramblett DE
Front Oncol; 2022; 12():940019. PubMed ID: 35965554
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on immunotherapy via oncolytic viruses.
Reale A; Vitiello A; Conciatori V; Parolin C; Calistri A; Palù G
Infect Agent Cancer; 2019; 14():5. PubMed ID: 30792754
[TBL] [Abstract][Full Text] [Related]
13. Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy.
Robilotti E; Zeitouni NC; Orloff M
Front Mol Biosci; 2023; 10():1178382. PubMed ID: 37795219
[TBL] [Abstract][Full Text] [Related]
14. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
15. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Viruses in Cancer Treatment: A Review.
Lawler SE; Speranza MC; Cho CF; Chiocca EA
JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
18. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy.
Reale A; Calistri A; Altomonte J
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959474
[TBL] [Abstract][Full Text] [Related]
19. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
20. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
Tian Y; Xie D; Yang L
Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]